{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:46:24Z","timestamp":1787021184262,"version":"build-2736575974"},"reference-count":42,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>In urothelial carcinoma, prior studies have indicated that the basal\/squamous molecular subtype and the presence of select DNA damage response (DDR) gene alterations are associated with improved benefit from cisplatin-based chemotherapy. We sought to evaluate these biomarkers in specimens from the phase III Cancer and Leukemia Group B (CALGB) 90601 trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We performed whole-transcriptome sequencing (n = 188) and exon capture DNA sequencing (n = 208) on pretreatment tumors from the CALGB 90601 randomized trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with treatment-na\u00efve metastatic bladder cancer. Whole-exome sequencing (WES) was performed on tumors from 22 patients who exhibited rapid progression or durable response. Tumors were assigned to molecular subtypes using three different classifiers. Proportional hazards model was used to correlate molecular subtype with overall survival (OS) and progression-free survival (PFS), adjusting for stratification factors and treatment arm (for PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Patients with basal tumors had the shortest PFS and OS in the entire cohort. PFS was numerically longer in patients with basal tumors receiving bevacizumab. DDR gene alterations were not associated with improved outcomes.\n                      <jats:italic toggle=\"yes\">FRY<\/jats:italic>\n                      , a candidate predictive biomarker of chemosensitivity identified by WES, did not confer sensitivity to cisplatin or gemcitabine in functional studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      Molecular subtype and DDR alterations did not correlate with improved outcomes in CALGB 90601. Possible explanations for these results include the small cohort size, lack of strong therapeutic effects of the treatments, genomic heterogeneity between profiled specimens and the metastatic lesions under treatment pressure, and differences in biology associated with different disease states (muscle-invasive\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      metastatic disease).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-24-00938","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:59:32Z","timestamp":1751385572000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct00942331","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-6099","authenticated-orcid":true,"given":"Gopa","family":"Iyer","sequence":"first","affiliation":[{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1088-9539","authenticated-orcid":true,"given":"Woonyoung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3983-5676","authenticated-orcid":true,"given":"Bin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics &amp; Bioinformatics, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2378-6512","authenticated-orcid":true,"given":"Filipe","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Division of Urology, Brigham and Women's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0676-942X","authenticated-orcid":true,"given":"Timothy","family":"Hanlon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1373-5295","authenticated-orcid":true,"given":"Henning","family":"Reis","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Hospital Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6296-2473","authenticated-orcid":true,"given":"Brendan J.","family":"Guercio","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-1237","authenticated-orcid":true,"given":"Megan","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Mountain","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7412-0481","authenticated-orcid":true,"given":"Mingxiao","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-1852","authenticated-orcid":true,"given":"Ashley M.","family":"Regazzi","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"McCart","sequence":"additional","affiliation":[{"name":"The Alliance Biobank at the Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wen","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2938-6627","authenticated-orcid":true,"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[{"name":"Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7939-7343","authenticated-orcid":true,"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":true,"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0552-6912","authenticated-orcid":true,"given":"Robert","family":"Dreicer","sequence":"additional","affiliation":[{"name":"University of Virginia Cancer Center, Charlottesville, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-9040","authenticated-orcid":true,"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[{"name":"UCHealth University of Colorado Hospital, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-2777","authenticated-orcid":true,"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[{"name":"Department of Biostatistics &amp; Bioinformatics, Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1971-0638","authenticated-orcid":false,"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[{"name":"Department of Urology, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2637-4249","authenticated-orcid":true,"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610292104"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0623"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1056"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.0158"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1001"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.009"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1318376111"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0077-T"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.034"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.8595"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9084-9"},{"key":"e_1_3_9_17_2","first-page":"4866","article-title":"The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy","volume":"6","author":"Inoue K","year":"2000","unstructured":"Inoue K, Slaton JW, Karashima T, et al: The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6:4866-4873, 2000","journal-title":"Clin Cancer Res"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.04.008"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-2879-2"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6067"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.09.006"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00286"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32365-6"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4333"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.438"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2520"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.009"},{"key":"e_1_3_9_30_2","article-title":"Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)","volume":"42","author":"Galsky MD","year":"2024","unstructured":"Galsky MD, Grande E, Necchi A, et al: Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001). J Clin Oncol 42, 2024 (suppl 4; abstr TPS717)","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52915-0"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111859"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01326-9"},{"key":"e_1_3_9_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.03.001"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01643"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29441-y"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.10.016"},{"key":"e_1_3_9_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0053-3"},{"key":"e_1_3_9_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2073"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4175"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-24-00938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:59:34Z","timestamp":1751385574000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-24-00938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1200\/PO-24-00938"],"URL":"https:\/\/doi.org\/10.1200\/po-24-00938","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"2024-12-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400938"}}